Expression and Clinical Significance of CXCR5 and LAG ‐3 on Peripheral Blood CD8 + T Cells in Patients With Diffuse Large B‐Cell Lymphoma
The Kaohsiung Journal of Medical Sciences · 2025
DOI: 10.1002/kjm2.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Xi-Zhe Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China. Hauptthemen laut MEDLINE: Receptors, CXCR5, CD8-Positive T-Lymphocytes, Lymphoma, Large B-Cell, Diffuse, Antigens, CD. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) exhibits substantial biological and clinical heterogeneity. This study investigated the expression and prognostic implications of C‐X‐C chemokine receptor type 5 (CXCR5) and lymphocyte activation gene‐3 (LAG‐3) on peripheral blood CD8 + T cells in patients with DLBCL. A total of 71 DLBCL patients and 71 healthy controls were enrolled. The expression levels of CXCR5 and LAG‐3 on peripheral blood CD8 + T cells were assessed and analyzed for their impact on 5‐year progression‐free survival (PFS) and overall survival (OS). Results revealed significantly elevated CXCR5 and LAG‐3 expression levels in DLBCL patients compared to controls. CXCR5 expression correlated with lactate dehydrogenase (LDH) levels, extranodal involvement, Ann Arbor stage, and International Prognostic Index (IPI) scores, while LAG‐3 expression was associated with Eastern Cooperative Oncology Group (ECOG) scores, number of extranodal sites, bone marrow involvement, Ann Arbor stage, and IPI scores. Multivariate analysis identified advanced age, Ann Arbor stage III‐IV, and elevated CXCR5 and LAG‐3 expression as independent risk factors for poorer 5‐year PFS and OS. Furthermore, patients with higher CXCR5 and LAG‐3 expression levels demonstrated significantly reduced 5‐year PFS and OS rates. In conclusion, elevated CXCR5 and LAG‐3 expression on peripheral blood CD8 + T cells plays a pivotal role in DLBCL progression and prognosis, making these markers potential therapeutic targets or prognostic indicators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
ORCID-Profile: Shi-Xin Wu
Zitieren
APA
Guo, X. Z., Guo, Y. F., & Wu, S. X. (2025). Expression and Clinical Significance of CXCR5 and LAG ‐3 on Peripheral Blood CD8 + T Cells in Patients With Diffuse Large B‐Cell Lymphoma. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70005
Vancouver
Guo XZ, Guo YF, Wu SX. Expression and Clinical Significance of CXCR5 and LAG ‐3 on Peripheral Blood CD8 + T Cells in Patients With Diffuse Large B‐Cell Lymphoma. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.70005
BibTeX
@article{Guo2025,
author = {Guo, Xi-Zhe and Guo, Ya-Fei and Wu, Shi-Xin},
title = {Expression and Clinical Significance of CXCR5 and LAG ‐3 on Peripheral Blood CD8 + T Cells in Patients With Diffuse Large B‐Cell Lymphoma},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2025},
doi = {10.1002/kjm2.70005}
}
EUVIMED